Zulvac SBV
Inactivated Schmallenberg virus, strain BH80/11-4
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Zulvac SBV. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Zulvac SBV.
For practical information about using Zulvac SBV, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Zulvac SBV
|
Agency product number |
EMEA/V/C/002781
|
Active substance |
Inactivated Schmallenberg virus, strain BH80/11-4
|
International non-proprietary name (INN) or common name |
Inactivated Schmallenberg virus, strain BH80/11-4
|
Species |
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI02AA
|
Publication details | |
---|---|
Marketing-authorisation holder |
Zoetis Belgium SA
|
Revision |
3
|
Date of issue of marketing authorisation valid throughout the European Union |
06/02/2015
|
Contact address |
Rue Laid Burniat 1 |
Product information
15/01/2020 Zulvac SBV - EMEA/V/C/002781 - R/0007
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Immunologicals for bovidae
-
Inactivated viral vaccines
Therapeutic indication
For active immunisation of cattle and sheep from 3.5 months of age to prevent viraemia associated with infection by Schmallenberg virus.